Six potential biomarkers for bladder cancer: key proteins in cell-cycle division and apoptosis pathways.

IF 2.1 Q3 ONCOLOGY
Güldal Inal Gültekin, Özlem Timirci Kahraman, Murat Işbilen, Saliha Durmuş, Tunahan Çakir, İlhan Yaylim, Turgay Isbir
{"title":"Six potential biomarkers for bladder cancer: key proteins in cell-cycle division and apoptosis pathways.","authors":"Güldal Inal Gültekin,&nbsp;Özlem Timirci Kahraman,&nbsp;Murat Işbilen,&nbsp;Saliha Durmuş,&nbsp;Tunahan Çakir,&nbsp;İlhan Yaylim,&nbsp;Turgay Isbir","doi":"10.1186/s43046-022-00153-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The bladder cancer (BC) pathology is caused by both exogenous environmental and endogenous molecular factors. Several genes have been implicated, but the molecular pathogenesis of BC and its subtypes remains debatable. The bioinformatic analysis evaluates high numbers of proteins in a single study, increasing the opportunity to identify possible biomarkers for disorders.</p><p><strong>Methods: </strong>The aim of this study is to identify biomarkers for the identification of BC using several bioinformatic analytical tools and methods. BC and normal samples were compared for each probeset with T test in GSE13507 and GSE37817 datasets, and statistical probesets were verified with GSE52519 and E-MTAB-1940 datasets. Differential gene expression, hierarchical clustering, gene ontology enrichment analysis, and heuristic online phenotype prediction algorithm methods were utilized. Statistically significant proteins were assessed in the Human Protein Atlas database. GSE13507 (6271 probesets) and GSE37817 (3267 probesets) data were significant after the extraction of probesets without gene annotation information. Common probesets in both datasets (2888) were further narrowed by analyzing the first 100 upregulated and downregulated probesets in BC samples.</p><p><strong>Results: </strong>Among the total 400 probesets, 68 were significant for both datasets with similar fold-change values (Pearson r: 0.995). Protein-protein interaction networks demonstrated strong interactions between CCNB1, BUB1B, and AURKB. The HPA database revealed similar protein expression levels for CKAP2L, AURKB, APIP, and LGALS3 both for BC and control samples.</p><p><strong>Conclusion: </strong>This study disclosed six candidate biomarkers for the early diagnosis of BC. It is suggested that these candidate proteins be investigated in a wet lab to identify their functions in BC pathology and possible treatment approaches.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"34 1","pages":"54"},"PeriodicalIF":2.1000,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760318/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-022-00153-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The bladder cancer (BC) pathology is caused by both exogenous environmental and endogenous molecular factors. Several genes have been implicated, but the molecular pathogenesis of BC and its subtypes remains debatable. The bioinformatic analysis evaluates high numbers of proteins in a single study, increasing the opportunity to identify possible biomarkers for disorders.

Methods: The aim of this study is to identify biomarkers for the identification of BC using several bioinformatic analytical tools and methods. BC and normal samples were compared for each probeset with T test in GSE13507 and GSE37817 datasets, and statistical probesets were verified with GSE52519 and E-MTAB-1940 datasets. Differential gene expression, hierarchical clustering, gene ontology enrichment analysis, and heuristic online phenotype prediction algorithm methods were utilized. Statistically significant proteins were assessed in the Human Protein Atlas database. GSE13507 (6271 probesets) and GSE37817 (3267 probesets) data were significant after the extraction of probesets without gene annotation information. Common probesets in both datasets (2888) were further narrowed by analyzing the first 100 upregulated and downregulated probesets in BC samples.

Results: Among the total 400 probesets, 68 were significant for both datasets with similar fold-change values (Pearson r: 0.995). Protein-protein interaction networks demonstrated strong interactions between CCNB1, BUB1B, and AURKB. The HPA database revealed similar protein expression levels for CKAP2L, AURKB, APIP, and LGALS3 both for BC and control samples.

Conclusion: This study disclosed six candidate biomarkers for the early diagnosis of BC. It is suggested that these candidate proteins be investigated in a wet lab to identify their functions in BC pathology and possible treatment approaches.

Abstract Image

Abstract Image

Abstract Image

膀胱癌的六个潜在生物标志物:细胞周期分裂和凋亡途径的关键蛋白。
背景:膀胱癌的病理是由外源性环境因素和内源性分子因素共同引起的。一些基因已被牵连,但BC及其亚型的分子发病机制仍有争议。生物信息学分析在一项研究中评估了大量蛋白质,增加了识别疾病可能的生物标志物的机会。方法:本研究的目的是利用几种生物信息学分析工具和方法鉴定BC的生物标志物。在GSE13507和GSE37817数据集中对BC和正常样本的每个问题集进行T检验比较,并在GSE52519和E-MTAB-1940数据集中对统计问题集进行验证。采用差异基因表达、层次聚类、基因本体富集分析和启发式在线表型预测算法等方法。在Human Protein Atlas数据库中评估具有统计学意义的蛋白质。GSE13507 (6271 probesets)和GSE37817 (3267 probesets)的数据在提取不含基因注释信息的probesets后显著。通过分析BC样本中前100个上调和下调的问题集,进一步缩小了两个数据集中(2888个)的共同问题集。结果:在400个问题集中,68个问题集对两个数据集具有相似的fold-change值(Pearson r: 0.995)。蛋白质-蛋白质相互作用网络显示CCNB1、BUB1B和AURKB之间有很强的相互作用。HPA数据库显示,BC和对照样本中CKAP2L、AURKB、APIP和LGALS3的蛋白表达水平相似。结论:本研究揭示了BC早期诊断的六个候选生物标志物。建议在湿实验室中研究这些候选蛋白,以确定它们在BC病理中的功能和可能的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
46
审稿时长
11 weeks
期刊介绍: As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信